Navigation Links
Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
Date:12/18/2013

MENLO PARK, Calif. and INGELHEIM, Germany, Dec. 18, 2013 /PRNewswire/ -- Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders.  Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors.  Circuit Therapeutics' key technology, optogenetics, allows the control of individual nerve cells and circuits within the brain enabling their functional identification and characterization.  The combination of optogenetics and sophisticated molecular technologies provides an unprecedented level of focus to identify novel drug targets and approaches for drug development. The new insights enabled by circuit-based analysis provide fundamentally differentiated approaches to understanding and treating brain disorders, which have otherwise been difficult to address.

(Logo: http://photos.prnewswire.com/prnh/20131218/SF34780LOGO)

Under the terms of the agreement the research and development capabilities of the two companies will be brought together to provide novel avenues for drug discovery in a three-year research program.  Further details of the agreement are not disclosed.

"We are excited to work with Boehringer Ingelheim to utilize Circuit's unique capabilities to advance drug discovery. The innovative and ambitious vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with Circuit's innovative technologies makes an ideal partnership. We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients' lives," said Fred Moll, Chairman of Circuit Therapeutics.

"We are very enthusiastic about being able to work in a partnership with Circuit Therapeutics, one of the leading organizations in the field of circuit biology and optogenetics," said Dr. Bernd Sommer, the head of neuroscience research at Boehringer Ingelheim.  "We believe that, by working together to investigate maladaptive brain circuitry with this exciting approach, we will be able to obtain a better understanding of the neurobiological basis of human neuropsychiatric disorders, thereby allowing us to make a difference to science, disease and patients."

About Circuit Therapeutics
Circuit Therapeutics is a privately held discovery stage biotechnology company based in Menlo Park, California. The company's cutting edge technologies focused on neural circuits are being applied to enable new ways of drug discovery and development of direct therapeutic interventions across a broad range of indications.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com

Contact:
Boehringer Ingelheim
Dr. Reinhard Malin
Director Corporate Communications
Tel.: +49 (6132) 77-90815
reinhard.malin@boehringer-ingelheim.com

Boehringer Ingelheim US (for US media enquiries)
Sperry Mylott
Senior Associate Director, U.S. Corporate Communications
Tel.: (203) 798-4630
sperry.mylott@boehringer-ingelheim.com

Circuit Therapeutics
Dr. Karoly Nikolich
President and Founder
1505 O'Brien Drive
Menlo Park, California 94025
Tel.: (650) 543-1401
knikolich@circuittx.com


'/>"/>
SOURCE Circuit Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnetics Ruggedized Strip Connectors Provide Fast and Firm Mating for High Density Circuits in Miniature and Portable Electronics
2. Women Injured by Bestselling Diabetes Drug Lipitor Take on Pfizer in St. Louis Circuit Court
3. Human Circuit Recognized as Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2013
4. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
5. Human Circuit Recognized as an Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2012
6. Analog Integrated Circuits (IC) Market to 2016 - Electric Vehicles and Portable Medical Equipment Segments to be Main Source of Future Growth
7. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
8. Halozyme Therapeutics Announces Executive Transitions
9. Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
10. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
11. Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):